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ABSTRACT 
 
All members registered on the managed care database for the chronic condition 
Rheumatoid Arthritis (RA), for the period 01 January 2003 to 30 June 2003, were 
evaluated to determine the prescribing pattern of the cyclo-oxygenase (COX) II inhibitors 
and non-selective non-steroidal anti-inflammatory (NSAIDs). A total of 2818 members 
were registered on the managed care database of the chronic condition RA and 1372 
members were identified as using COX II inhibitors and 827 members were using non-
steroidal anti-inflammatory (NSAIDs). The prescribing frequency determined for the 
COX II inhibitors were 48.60% and 29.35% for the NSAIDs.  The members identified as 
either using a COX II inhibitor or a NSAIDs were divided into two groups. The 
prescribing patterns of each group such as age, gender, co-morbid conditions, 
concomitant medication use and frequency were analysed and compared to the national 
institute of clinical excellence (NICE) and the South African Rheumatism and Arthritis 
Association (SARAA) guidelines for the appropriate prescribing of the COX II inhibitors. 
Celecoxib was the most frequently prescribed COX II inhibitor accounting for 46% of all 
the COX II inhibitors identified and diclofenac was the most frequently prescribed 
NSAID accounting for 34% of all the  NSAIDs prescriptions. COX II inhibitors were 
prescribed more frequently to females with a mean age of 55 years than males. A similar 
prescribing trend was found with the NSAIDs. The COX II inhibitors were frequently 
prescribed to patients over the age of 56 with co morbid gastro-oesophageal disease and 
concomitant warfarin and steroid use. The prescribing patterns found in the managed care 
environment were similar to those recommended by the NICE and SARAA guidelines.  
The managed care data showed that the COX II inhibitors, which are supposed to have 
less gastric adverse side effects, were frequently used in combination with gastro-
protective agents (GPA’s).  
 
This study indicates that even though COX II inhibitors were prescribed more frequently 
than NSAIDs in the managed care environment the recommended clinical guidelines and 
protocols employed by the managed care environment were adhered to.  However, there 
 v
is a need to closely monitor patients on concomitant GPA’s treatment and COX II 
inhibitors. 
 
This study helped to evaluate the current prescribing patterns of COX II inhibitors in the 
managed health care environment. This study confirmed that guidelines and protocols 
were adhered to. These are excellent tools to be used in the managed health care 
environment to ensure effective and appropriate prescribing. 
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